CRVL vs MGRC vs GBLI vs MCRB vs AMSF

For growth investors, CorVel Corporation (CRVL) is the stronger pick with 12.

6% revenue growth year-over-year, versus 2. 0% for Global Indemnity Group, LLC (GBLI). Seres Therapeutics, Inc. (MCRB) offers the better valuation at 12. 1x trailing P/E, making it the more compelling value choice. Analysts rate McGrath RentCorp (MGRC) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Seres Therapeutics, Inc.

(MCRB) is the cheapest at 12. 1x versus CorVel Corporation at 31. 7x. On forward P/E, Global Indemnity Group, LLC is actually cheaper at 9. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McGrath RentCorp (MGRC) delivered a total return of +49.

0%, compared to -98. 1% for Seres Therapeutics, Inc. (MCRB). Over 10 years, the gap is even starker: MGRC returned +401. 5% versus MCRB's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Global Indemnity Group, LLC (GBLI) is the lower-risk stock at 0.

14β versus Seres Therapeutics, Inc. 's 1. 69β — meaning MCRB is approximately 1126% more volatile than GBLI relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CorVel Corporation (CRVL) is pulling ahead at 12.

6% versus 2. 0% for Global Indemnity Group, LLC (GBLI). On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc. grew EPS 103. 4% year-over-year, compared to -43. 9% for Global Indemnity Group, LLC. Over a 3-year CAGR, MGRC leads at 14. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus 5. 6% for Global Indemnity Group, LLC — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGRC leads at 25. 9% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — GBLI leads at 49. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Global Indemnity Group, LLC (GBLI) trades at 9.

7x forward P/E versus 33. 4x for CorVel Corporation — 23. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMSF: 46. 9% to $44. 50.

In this comparison, AMSF (8.

4% yield), GBLI (5. 1% yield), MGRC (1. 7% yield) pay a dividend. CRVL, MCRB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Global Indemnity Group, LLC (GBLI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

14), 5. 1% yield). Seres Therapeutics, Inc. (MCRB) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GBLI: +17. 7%, MCRB: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CRVL (Financial Services) and MGRC (Industrials) and GBLI (Financial Services) and MCRB (Healthcare) and AMSF (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CRVL is a small-cap quality compounder stock; MGRC is a small-cap quality compounder stock; GBLI is a small-cap deep-value stock; MCRB is a small-cap deep-value stock; AMSF is a small-cap deep-value stock. MGRC, GBLI, AMSF pay a dividend while CRVL, MCRB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.